Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Molnupiravir in COVID-19: A Scoping Review

Author(s): Shilpa Kaore and Shubham Atal*

Volume 14, Issue 3, 2022

Published on: 21 July, 2022

Page: [203 - 214] Pages: 12

DOI: 10.2174/2589977514666220527105158

Price: $65

Abstract

Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity. It has initiated an era of research on repurposed drugs such as hydroxychloroquine, lopinavir/ritonavir, corticosteroids, remedesivir, ivermectin, alongside selective antivirals to treat or prevent COVID- 19. Molnupiravir is an orally available emerging antiviral drug considered highly promising for COVID-19.

Methods and Results: We have performed a scoping review for the use of molnupiravir against SARS-CoV-2 and COVID-19. It acts by inhibiting RNA-dependent RNA polymerase (RdRp), and exhibits broad-spectrum antiviral activity. Preclinical studies have evaluated the therapeutic efficacy as well as prophylactic activity of molnupiravir against SARS CoV-2 in various animal models that include ferrets, hamsters, mice, immunodeficient mice implanted with human lung tissue and cell cultures, in various doses ranging from 5-300 mg/kg, and results have been encouraging. Initial evidence of safety and efficacy from early phase clinical studies has been encouraging too, and recent results from a large phase 3 global trial have shown significant benefits among symptomatic outpatients. Other late-phase clinical trials are still underway with the aim of establishing molnulpiravir as a therapeutic option for COVID-19, particularly for non-hospitalized patients.

Conclusion and Relevance: On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.

Keywords: Molnupiravir, COVID-19, SARS-CoV-2, EIDD-2801, MK-4482, clinical, preclinical.

« Previous Next »
[1]
WHO Coronavirus. (COVID-19) Dashboard; , 2021. Available from: https://covid19.who.int/
[2]
Centers for disease control and prevention. symptoms of COVID19 Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (Accessed on 29 June, 2021).
[3]
Delang, L.; Neyts, J. Medical treatment options for COVID-19. Eur Hear J Acute Cardiovasc Care, 2020, 204887262092279.
[4]
Armstrong, M. Evaluate Vantage. Molnupiravir’s big day draw near., 2021. Available from: https://www.evaluate.com/vantage/articles/news/trial-results/molnupiravirs-big-day-draws-near (Accessed on April 27, 2021).
[5]
Stuyver, L.J.; Whitaker, T.; McBrayer, T.R. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C vi-ruses in culture. Antimicrob. Agents Chemother., 2003, 47(1), 244-254.
[http://dx.doi.org/10.1128/AAC.47.1.244-254.2003] [PMID: 12499198]
[6]
Urakova, N.; Kuznetsova, V.; Crossman, D.K. beta-d-N (4)-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol., 2018, 92(3), e01965-e17.
[http://dx.doi.org/10.1128/JVI.01965-17] [PMID: 29167335]
[7]
Wahl, A.; Gralinski, L.E.; Johnson, C.E. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, 591(7850), 451-457.
[http://dx.doi.org/10.1038/s41586-021-03312-w] [PMID: 33561864]
[8]
Pan, H.; Peto, R.; Henao-Restrepo, A.M. Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N. Engl. J. Med., 2021, 384(6), 497-511.
[http://dx.doi.org/10.1056/NEJMoa2023184] [PMID: 33264556]
[9]
Businesswire. Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial. 2020. Available from: https://www.businesswire.com/news/home/20200707005891/en (Accessed on 22 April, 2021).
[10]
FDA News Release. Coronavirus (COVID-19) Update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults; , 2021. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain (Accessed on 24 December, 2021)
[11]
U.K.’s medicines and healthcare products regulatory agency authorizes molnupiravir for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. 2021. Available from: https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/ (Accessed on 5 November, 2021).
[12]
Toots, M.; Yoon, J.J.; Cox, R.M. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med., 2019, 11(515), eaax5866.
[http://dx.doi.org/10.1126/scitranslmed.aax5866] [PMID: 31645453]
[13]
Kabinger, F.; Stiller, C.; Schmitzová, J. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. bioRxiv, , 2021.05.11.443555.
[http://dx.doi.org/10.1101/2021.05.11.443555]
[14]
Rosenke, K.; Hansen, F.; Schwarz, B. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat. Commun., 2021, 12(1), 2295.
[http://dx.doi.org/10.1038/s41467-021-22580-8] [PMID: 33863887]
[15]
Dolgin, E. The race for antiviral drugs to beat COVID - and the next pandemic. Nature, 2021, 592(7854), 340-343.
[http://dx.doi.org/10.1038/d41586-021-00958-4] [PMID: 33854246]
[16]
Gordon, C.J.; Tchesnokov, E.P.; Schinazi, R.F.; Götte, M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem., 2021, 297(1), 100770.
[http://dx.doi.org/10.1016/j.jbc.2021.100770] [PMID: 33989635]
[17]
Cox, R.M.; Wolf, J.D.; Plemper, R.K. Therapeutic MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. research square, 2021.
[http://dx.doi.org/10.21203/rs.3.rs-89433/v1]
[18]
Sheahan, T.P.; Sims, A.C.; Zhou, S. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med., 2020, 12(541), eabb5883.
[http://dx.doi.org/10.1126/scitranslmed.abb5883] [PMID: 32253226]
[19]
Abdelnabi, R.; Foo, C.S.; Kaptein, S.J.F. The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of anti-viral efficacy in a SARS-CoV-2 hamster infection model. bioRxiv, , 2020.12.10.419242.
[http://dx.doi.org/10.1101/2020.12.10.419242]
[20]
Joshi, S.; Parkar, J.; Ansari, A. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis., 2021, 102, 501-508.
[http://dx.doi.org/10.1016/j.ijid.2020.10.069] [PMID: 33130203]
[21]
Abdelnabi, R.; Foo, C.S.; De Jonghe, S.; Maes, P.; Weynand, B.; Neyts, J. Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. J. Infect. Dis., 2021, 224(5), 749-753.
[http://dx.doi.org/10.1093/infdis/jiab361] [PMID: 34244768]
[22]
Painter, WP; Holman, W; Bush, JA Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against sARS-CoV-2. Antimicrob Agents Chemother, 2021, 65, AAC.02428-20. Advance online publication
[http://dx.doi.org/10.1128/AAC.02428-20] [PMID: 33649113]
[23]
Khoo, S.H.; FitzGerald, R.; Fletcher, T. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: A phase 1, dose-escalating, randomised controlled study medRxiv, , 2021.05.03.21256309.
[http://dx.doi.org/10.1101/2021.05.03.21256309]
[24]
The AGILE Clinical Trial Platform. 2020. Available from: https://www.agiletrial.net/ (Accessed 24 December, 2021).
[25]
National Library of Medicine (U.S.). AGILE: seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment. A randomised Phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04746183 (Accessed 15 May, 2021).
[26]
Kenilworth, N.J. (Businesswire) ridgeback biotherapeuticS and merck announce preliminary findings from a phase 2a trial of investigational COVID-19 therapeutic molnupiravir 2021. Available from: https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/ (Accessed on 15 May, 2021).
[27]
National Library of Medicine (U.S.). A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04405570 (Accessed 15 May, 2021).
[28]
Fischer, W.; Eron, J.J.; Holman, W. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv, 2021, 2021.06.17.21258639.
[http://dx.doi.org/10.1101/2021.06.17.21258639]
[29]
National Library of Medicine (U.S.). A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in NonHospitalized Adults With COVID-19. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04575597 (Accessed 15 May, 2021).
[30]
Kenilworth, N.J. (Businesswire) Merck and Ridgeback biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate COVID-19; , 2021. Available from: https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/ (Accessed on 17 May 2021)
[31]
Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. 2021. Available from: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ (Accessed on 08 October, 2021).
[32]
News. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ, 2021, 375(2422)
[33]
National Library of Medicine (U.S.). A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04575584 (Accessed 15 May, 2021).
[34]
National Library of Medicine (U.S.). The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2., 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04405739 (Accessed 15 May, 2021).
[35]
National Library of Medicine (U.S.). Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK4482-013) (MOVe-AHEAD). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04405739 (Accessed 10 Oct, 2021).
[36]
Molnupiravir, S.R. A multi-center, Phase- III clinical trial of Molnupiravir capsules. 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 30 May, 2021).
[37]
Search Result Molnupiravir. A Phase II/III Clinical Trial to understand the efficacy and safety of Molnupiravir 800mg in the treatment of patients diagnosed with moderate COVID-19. 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[38]
Search Result Molnupiravir. A clinical study to estimate the efficacy and safety of formulation of Molnupiravir in patients with Mild COVID-19 infection., 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[39]
Search Result Molnupiravir. To Evaluate the Efficacy and Safety of Molnupiravir Capsule in Treatment of Subjects with Mild Corona virus Disease (COVID-19). 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[40]
Search Result Molnupiravir. A Phase III Clinical Trial to understand the efficacy and safety of Molnupiravir 800mg in the treatment of patients diagnosed with mild COVID-19. 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[41]
Search Result Molnupiravir. Clinical Trial to Evaluate the Efficacy and Safety of Molnupiravir Capsule in Treatment of Subjects with Moderate Coronavirus Disease (COVID-19) 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[42]
Search Result Molnupiravir. A Clinical Study with Molnupiravir Capsules 800mg in COVID-19 Patients with Mild symptoms. 2021. Available from: http://ctri.nic.in/Clinicaltrials/advsearch.php (Accessed 1 October, 2021).
[43]
Singh, S.; Kumar Mitra, A.; Arora, N. Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19., Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/ (Accessed 9 October).
[44]
Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 2019, 17(3), 181-192.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[45]
Cohen, J.; Charles, P. Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug. Science. 2020. Available from: https://www.sciencemag.org/news/2020/05/emails-offer-look-whistleblower-charges-cronyism-behind-potential-covid-19-drug (Accessed on 17 May, 2021).
[46]
FDA/CEDR resources page. Food and Drug Administration Web site. 2021. Available from: https://www.fda.gov/media/155053/download (Accessed 7 Feb, 2022).
[47]
Jayk Bernal, A; Gomes da Silva, MM; Musungaie, DB Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med, 2021, NEJMoa2116044.
[48]
Clinical Trial Registry - India (CTRI). Molnupiravir Available from: http://www.ctri.nic.in (Accessed on 15 July, 2021).
[49]
WHO Coronavirus. (COVID-19) Dashboard. Situation by Region, Country, Territory & Area Available from: https://covid19.who.int/table (Accessed on 30 November, 2021).
[50]
Update on Omicron. World Health Organization Available from: https://www.who.int/news/item/28-11-2021-update-on-omicron (Accessed on 30 November, 2021).
[51]
Kim, P.S.; Read, S.W.; Fauci, A.S. Therapy for early COVID-19: A critical need. JAMA, 2020, 324(21), 2149-2150.
[http://dx.doi.org/10.1001/jama.2020.22813] [PMID: 33175121]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy